OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung Cancer

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.

The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.